EILEAN THERAPEUTICS INITIATES FIRST IN HUMAN TRIAL WITH EILETOCLAX, A SELECTIVE BCL2 INHIBITOR WITH LIMITED IMMUNE SUPPRESSION AND IMPROVED SAFETY COMPARED TO VENETOCLAX AND VENETOCLAX-LIKE MOLECULES

/PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule...

Related Keywords

Australia ,Dover ,Tasmania ,Johnc Byrd , ,Human Research Ethics Committee ,Expert Systems Inc ,Prnewswire Eilean Therapeutics ,Eilean Therapeutics ,Iain Dukes ,Chief Executive Officer ,Torrey Pines Investment ,